Colacicco v Apotex Inc. and the Federal Preemption of State Tort Remedies for Health Injuries: Implications for Public Health Policy and Practice

521 F.3d 253 (3rd Cir. 2008).

128 S. Ct. 999 (2008).

Harris G. Report assails F.D.A. oversight of clinical trials. The New York Times 2007 Sep 28.

Harris G. F.D.A. Chief writes Congress for money. The New York Times 2008 May 14.

Gostin LO . Public health law: Power, duty, restraint. Berkeley (CA): University of California Press; 2000.

521 F.3d 253 (3rd Cir. 2008) citing Hillsborough County v Automated Med. Labs., Inc., 471 U.S. 707 (1985).

21 C.F.R. §314.70(c).

944 A.2d 179 (Vt. 2006).

Labaton S. “Silent tort reform” is overriding states' powers. The New York Times 2006 Mar 10; Sect. C:5.

Sharkey CM . Preemption by preamble: Federal agencies and the federalization of tort law. DePaul Law Rev 2007;56:227.

Kessler DA Vladeck DC . A critical examination of the FDA's efforts to preempt failure-to-warn claims [citing Porter MJ. The Lohr decision: FDA perspective and position. Food Drug Law J 1997;52:7–11]. Georgetown Law J 2008;96:461–95.

Requirements on content and format of labeling for human prescription drugs and biological products, 71 Fed. Reg. 3922, 3934 (2006 Jan 24) (to be codified at 21 C.F.R. pts. 201, 314, 601).

Skidmore v Swift & Co., 323 U.S. 134 (1944).

Schweitzer SO . Trying times at the FDA—the challenge of ensuring the safety of imported pharmaceuticals. N Engl J Med 2008;358:1773–7.

Food and Drug Administration (US). FDA science and mission at risk: Report of the subcommittee on science and technology. Rockville (MD): FDA (US); November 2007.

Wood AJ . Playing “kick the FDA”—risk-free to players but hazardous to public health. N Engl J Med 2008;358:1774–5.

Union of Concerned Scientists. News and views: Scientific integrity update: Dangerous interference in science at the FDA. Cambridge (MA): Union of Concerned Scientists; September 2006.

Office of Inspector General, Department of Health and Human Services (US). FDA's review process for new drug applications: A management review. Washington: DHHS (US); 2003.